BRIEF-Incyte To Acquire Vega Therapeutics, A Wholly Owned Subsidiary Of Star Therapeutics, Expanding Its Hematology Portfolio Into Bleeding Disorders

Incyte

Incyte

INCY

0.00

June 8 (Reuters) - Incyte Corp INCY.O:

  • INCYTE TO ACQUIRE VEGA THERAPEUTICS, A WHOLLY OWNED SUBSIDIARY OF STAR THERAPEUTICS, EXPANDING ITS HEMATOLOGY PORTFOLIO INTO BLEEDING DISORDERS

  • INCYTE - TO BUY VEGA THERAPEUTICS FOR $1.25 BILLION

  • INCYTE - DEAL VALUE UP TO $2 BILLION INCLUDING $750 MILLION IN SALES MILESTONES

  • INCYTE - DEAL EXPECTED TO CLOSE IN Q3 2026 WITH $1.25 BILLION RD CHARGE

Source text: ID:nBw1WY6D2a

Further company coverage: INCY.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.